Comprehensive Cancer Genomic Profiling Service


Find the Right Treatment For Your Cancer Patient

ACTOnco® +is developed with the aim of supporting and answering the clinical challenges faced during the management of major solid tumors, including carcinomas, sarcomas, and lymphomas. The ACTOnco<sup>®</sup>+ panel comprises 440 specially-curated genes, 13 fusion genes & more than 350 fusion transcripts and references the Hallmarks of Cancer to facilitate treatment strategies, including:Chemotherapy,Targeted therapy,Immunotherapy and Pharmacogenomics.

Cancer Signaling Pathway Analysis-Identify more treatment options with pathway integration

ACTOnco® comprehensively identifies genetic alterations of each signaling pathway to evaluate drug options based on upstream and downstream interactions. By incorporating comprehensive genomics profiling and integrating signaling pathway analysis, ACTOnco® + provides clinicians with a more holistic understanding of the major cancer-driven events during tumorigenesis and provides more targeted therapeutic strategies.

ACTOnco® +

Hallmark of ACTOnco® +

  1. Comprehensive Cancer Types

    All Solid Tumors
  2. Suitable for Most Patients

    - Newly diagnosed with complex cancer type

    - Recurrent and metastastic cases

    - Patient searching for treatment (and trials) options

    - Diagnosed with advanced cancer or late-stage cancer

  3. Comprehensive Report Content

    - Genetic alterations, including BRCA1/2

    - Therapeutic implications for FDA approved chemotherapy, hormonal therapy, targeted therapy, PARP1 inhibitors and immunotherapy drugs and other drugs used in clinical trials

    - Prediction of immunotherapy response, including TMB and MSI status

    - Pharmacogenomics information


Can Provide Comprehensive Solutions

  1. Comprehensive Pathway-Based Panel

    Sequencing of 440 cancer-related genes and 13 fusion genes & more than 350 fusion transcripts covering most key cancer signaling pathways for targeted therapy
  2. Predicting immunotherapy response

    Incorporating mutation burden, immune-related gene information and MSI status for a more accurate immunotherapy recommendation
  3. Providing Pharmacogenetics information

    Responses to treatment may be affected by inherited genetic variations (polymorphisms). Pharmacogenetics information can be used to match patients with the treatment that is most effective, while causing less side-effects.
  4. Pioneering Bioinformatics

    Integrating cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science, and pharmaceutical biology to provide insightful interpretation
  5. Providing Report Consultation

    Every report is complemented with a face-to-face consultation with our medical team.
  6. Short Turnaround Time

    Providing professional solutions within 10 working days. (starting from the day qualified specimen is received at lab) 
  7. High Sensitivity

    Next Generation Sequencing (NGS) is used for microscale specimens.


Next Generation Sequencing-ACTOnco®

440 Cancer-related genes ( TAT : 10 working days)

Target Region

> 1,000,000 bps

NGS Sequencing Mean Depth

≥ 500 X

Next Generation Sequencing-ACTFusion

Comprehensive testing of 13 fusion genes & more than 350 fusion transcripts ( TAT : 10 working days)

Prediction of Immunotherapy Response

Tumor Mutational Burden (TMB) 

Microsatellite instability (MSI) testing

Sample Types


.5-20 unstained sections (5 µm/slide)

.1H&E stained slide (5 µm)

*Cell block from pleural effusion, ascites or pericardial hydrops (≥1X106cells)

* Pleural effusion , ascites and pericardial hydrops samples need to be processed into cell blocks before sending to ACT Genomics.